Product and Geographic Information

12 Months Ended

Dec. 31, 2023

Segment Reporting [Abstract]

Product and Geographic Information

Product and Geographic Information

The Company's operations include the following product portfolios, which constitute one operating segment engaged in developing and delivering innovative health solutions through its portfolio of prescription therapies and medical devices within women's health, biosimilars and established brands.

Revenues of the Company's products were as follows:

	Year Ended December 31,
	2023						2022						2021
($ in millions)	U.S.		Int'l		Total		U.S.		Int'l		Total		U.S.		Int'l		Total
Women's Health
Nexplanon/Implanon NXT	$	572	$	257	$	830	$	573	$	261	$	834	$	532	$	237	$	769
Follistim AQ	125		136		262		105		124		229		110		127		237
NuvaRing	66		86		152		85		88		173		85		106		191
Ganirelix Acetate Injection	19		91		110		26		97		123		22		88		111
Marvelon/Mercilon	—		134		134		—		110		110		—		98		98
Jada	43		—		43		20		—		20		3		—		3
Other Women's Health (1)	72		101		171		90		94		184		96		111		206
Biosimilars
Renflexis	234		43		278		196		30		226		164		21		186
Ontruzant	46		109		155		48		74		122		34		92		126
Brenzys	—		73		73		—		75		75		—		63		63
Aybintio	—		43		43		—		39		39		—		36		36
Hadlima	17		26		44		—		19		19		—		13		13
Established Brands
Cardiovascular
Zetia	8		299		306		8		350		357		10		368		378
Vytorin	6		124		129		8		123		130		11		153		164
Atozet	—		519		519		—		457		457		—		458		458
Rosuzet	—		70		70		—		71		71		—		68		68
Cozaar/Hyzaar	10		272		281		13		310		323		12		345		357
Other Cardiovascular (1)	2		151		155		3		156		159		4		187		191
Respiratory
Singulair	11		393		404		11		400		411		15		398		413
Nasonex	—		252		253		10		229		238		4		201		206
Dulera	156		38		194		140		40		180		154		36		190
Clarinex	5		132		136		4		121		125		6		106		111
Other Respiratory (1)	49		28		77		46		36		83		56		33		89
Non-Opioid Pain, Bone and Dermatology
Arcoxia	—		257		257		—		241		241		—		244		244
Fosamax	3		156		159		4		148		152		4		172		175
Diprospan	—		91		91		—		122		122		—		125		125
Other Non-Opioid Pain, Bone and Dermatology (1)	14		261		275		15		257		273		16		269		286
Other
Proscar	1		96		97		1		99		101		1		116		117
Propecia	7		118		125		7		118		125		9		127		136
Other (1)	13		308		319		24		302		326		38		318		357
Other (2)	(1)		121		121		—		146		146		(3)		205		200
Revenues	$	1,478	$	4,785	$	6,263	$	1,437	$	4,737	$	6,174	$	1,383	$	4,921	$	6,304

Totals may not foot due to rounding. Trademarks appearing above in italics are trademarks of, or are used under license by, the Organon group of companies.

(1) Includes sales of products not listed separately. Revenues from Jada were previously reported as part of Other Women's Health. Revenue from an arrangement for the sale of generic etonogestrel/ethinyl estradiol vaginal ring is included in Other Women's Health.

(2) Includes manufacturing sales to Merck & Co., Inc. ("Merck") and third parties for current and prior periods.

Revenues by geographic area where derived are as follows:

	Year Ended December 31,
($ in millions)	2023		2022		2021
Europe and Canada	$	1,673	$	1,631	$	1,741
United States	1,478		1,437		1,383
Asia Pacific and Japan	1,129		1,143		1,173
China	864		917		933
Latin America, Middle East, Russia, and Africa	965		895		841
Other (1)	154		151		233
Revenues	$	6,263	$	6,174	$	6,304

(1) Primarily reflects manufacturing sales to Merck and third parties for current and prior periods.

As of December 31, 2023, approximately 71% of the Company's long-lived fixed assets are located in Europe and Canada, and 18% are in the United States. The Company does not disaggregate assets on a products and services basis for internal management reporting and, therefore, such information is not presented.